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Abstract.  Tissue transglutaminase  is a cytosolic en- 
zyme whose primary function is to catalyze the cova- 
lent cross-linking of proteins.  To investigate the func- 
tions of this enzyme in physiological systems, we have 
established lines of Balb-C 3T3 fibroblasts stably 
transfected with a constitutive tissue transglutaminase 
expression plasmid.  Several cell lines expressing high 
levels of catalytically active tissue transglutaminase 
have been isolated and characterized.  Transglutaminase- 
transfected cells showed morphologic features quite 
distinct from their nontransfected counterparts.  Many 
of the cells showed an extended and very flattened 
morphology that reflected increased adhesion of the 
cells to the substratum.  Other cells, particularly those 
showing the highest levels of intracellular transglu- 
taminase expression, showed extensive membrane bleb- 
bing and cellular fragmentation.  The results of these 
experiments suggest that the induction and activation 
of tissue transglutaminase  may contribute both to 
changes in cellular morphology and adhesiveness. 
T 
RANSGLUTAMINASES (TGases;  EC  2.3.2.13)  are  a 
family  of calcium-dependent enzymes that  catalyze 
the cross-linking  of proteins by promoting the forma- 
tion of isopeptide bonds between protein-bound glutamine 
and lysine residues (for a review see Folk, 1980; Lorand and 
Conrad,  1984;  Ichinose  et  al.,  1990;  Greenberg  et  al., 
1991). These enzymes are also capable of conjugating poly- 
amines  to proteins (Davies  et al.,  1988; Piacentini  et al., 
1988).  Several  transglutaminases  have now been isolated, 
cloned, and sequenced (Grundmann et al.,  1986; Ichinose 
et al., 1986; Ikura et al., 1988; Phillips et al., 1990; Gentile 
et al.,  1991; Kim et al., 1991), and it is clear that the trans- 
glutaminase activity appearing in different intracellular  and 
extracellular  compartments is the result of the activity of dis- 
tinct enzymes encoded by distinct  and unique genes. 
The extracellular  transglutaminases,  Factor XHI, and the 
transglutaminase  of seminal plasma, are involved in the clot- 
ring reactions of plasma proteins (for a review see W'tlliams- 
Ashman,  1984;  Ichinose  et al.,  1990;  Greenberg et al., 
1991). Much less is known of the function of the intracellu- 
lar  transglutaminases.  Keratinocyte transglutaminase  is  a 
membrane-bound intracellular  transglutaminase  whose ex- 
pression is restricted to skin and squamous epithelia  (Ta et 
al., 1990). This enzyme is induced during terminal differen- 
tiation of keratinocytes and cross-links  specific intracellular 
proteins contributing to the formation of the cornified cell 
envelope (Rice and Green,  1978; Thacher and Rice, 1985). 
The skin also contains a second intracellular  transglutamin- 
ase, epidermal transglutaminase,  whose function is not well 
understood (KJm et al.,  1990). 
Tissue transglutaminase  is an intracellular  transglutamin- 
ase found in many cells and tissues (Thomazy and Fesus, 
1989). Tissue transglutaminase  is involved in the process of 
apoptotic cell death  (Fesus et al.,  1987; Piacentini  et al., 
1991; Fesus et al.,  1992), the enzyme is induced and acti- 
vated in apoptotic cells and cross-linked proteins accumulate 
in the fragments  (apoptotic bodies) of cells undergoing pro- 
grammed cell death (Fesus et al.,  1989).  Tissue transglu- 
taminase has also been implicated  in the interactions  be- 
tween cells and the extracellular  matrix  (Bowness  et al., 
1987; Slife et al.,  1986; Tyrrel et al.,  1988; Kinsella  and 
Wight,  1986 and 1990). Transglntaminase  cross-linked  ma- 
trix proteins  have been shown to promote cellular adhesion 
(Fesus et al., 1986; Martinez et al., 1989; Sane et al., 1991), 
and the induction of tissue transglutaminase  has been shown 
to be correlated with morphological changes (Byrd et Licthi, 
1987; Nara et al., 1989) and increased adhesivity (Cai et al., 
1991) in several cultured cell lines. 
Conclusions on the physiological functions of tissue trans- 
glutaminase have been hampered by the lack of techniques 
capable of selectively modifying the activity of the enzyme 
in intact  cells.  Transglutaminase  inhibitors  have been used 
to deduce information on the function of this enzyme (Davies 
et al.,  1984),  but most of these inhibitors  are not entirely 
specific  and  can inhibit  other  enzymes and physiological 
processes (Cornwell et al., 1983; Lee et al., 1985). An alter- 
native approach has been to induce expression of the enzyme 
and then correlate changes in enzyme activity with biologi- 
cal responses.  Retinoic acid and sodium butyrate have both 
been reported to increase tissue transglutaminase  in some 
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Lee et al., 1987; Chiocca et al., 1989). However, both agents 
produce diverse effects on cellular function and it has been 
difficult to identify alterations in responses that are specifi- 
cally attributable to the induction of the transglutaminase, 
An alternative approach is to express the enzyme in cells by 
transfection with a constitutive expression vector. We have 
recently isolated a full-length eDNA clone for human tissue 
transglutaminase (Gentile et al.,  1991). In the studies re- 
ported here, we have introduced the cDNA for this enzyme 
into a eukaryotic expression vector and then have isolated 
lines of Balb-C 3T3 cells stably expressing high levels of the 
enzyme. Comparison of the phenotype of the transfected 
cells with that of their nontransfected counterparts, suggests 
that expression of tissue transglutaminase in these cells is as- 
sociated with both a marked alteration in cellular morphol- 
ogy, increased cell adhesion and blebbing, and cellular frag- 
mentation similar to that occurring during apoptotic cell 
death. 
Materials and Methods 
Human Tissue Transglutaminase Expression Vector 
An expression vector containing the human tissue transglutaminase eDNA 
was constructed by inserting a tissue transglutaminase eDNA (Gentile et 
al.,  1991) into the pSG5 DNA eukaryotic expression plasmid (Stratagene 
Inc., La Jolla, CA). This plasmid, which contains the SV-40 early gene pro- 
moter and the polyadenylation signal, was linearized with ECORI and the 
transglutaminase eDNA (3.3 kb) was ligated into the ECORI site of  the plas- 
mid (see Fig.  1). For cotransfection experiments, the pSV2-Neo plasmid 
(Clontech, Palo Alto, CA), containing the neomycin resistance gene under 
the control of the SV-40 early gene promoter, was used as a  selectable 
marker. 
Cell Culture and DNA Transfection 
COSA cells (obtained from Dr. B. de Crombrugghe, M. D. Anderson Can- 
cer Center, Houston, TX) were grown in alpha DME (Gibco Laboratories, 
Grand Island, NY) supplemented with 10% (vol/vol) heat-inactivated FBS 
(Hyclone Laboratories; Logan, UT), 50 u/mi penicillin, and 50 mcq/mi 
streptomycin (Gibco Laboratories). Balb-C 3T3 ceils (obtained from Dr. 
E. N. Olson, M. D, Anderson Cancer Center, Houston, TX) were grown 
in alpha DME supplemented with 10 % (vol/vol) heat-inactivated FBS, 10% 
(vol/vol) Serum Plus (Hazleton Research Products Inc.), 50 u/ml penicillin, 
and 50 meq/ml streptomycin. Ceils were grown at 37~  in a humidified at- 
mosphere containing 5% COz. Transfected Balb-C 3T3 cells were grown 
in alpha DME supplemented with 10%  (vol/vol) in normal growth media 
containing 400/~g/ml G418  (Geneticin; Gibco Laboratories). 
Transient transfection of COS-1 cells was carried out by using the DEAE- 
dextran procedure (Keown et al., 1990).  Balb-C 3T3 cell lines were trans- 
fected by cotransfecting 5  ￿  10  s in 10-cm dishes with 10 pg pSG5-TGase 
and  1 pg pSV2-Neo plasmid by calcium phosphate procedure (Cullen, 
B. R., 1987).  Stably transfected cells were selected and cloned in medium 
containing 400 pg/ml G418.  Confluent clonal cell lines were screened for 
human tissue transglntaminase expression by transglutaminase activity as- 
say (Lorand et al., 1972),  Northern blot (Ausubel et al., 1987),  and West- 
ern blot (Maniatis et al.,  1989)  analysis. 
Morphological and Immunochemical Analyses 
Cells, grown on coverslips, were fixed in the culture dish for 10 min at room 
temperature by addition of an equal volume of 8 % formaldehyde to the me- 
dia.  Coverslips were mounted with 50%  glycerol in TBS and studied by 
phase-contrast microscopy. 
Cells for immunocytochemistry were formaldehyde-fixed as described 
above  or  they  were  fixed  in  absolute  methanol  for  30  rain  at  4~ 
Formaldehyde-fixed cells were treated with 1% NaBH4 in TBS for 30 rain 
at room temperature to quench autofluorescence. The cells were permeabi- 
lized by 0.3 % Triton X-100 treatment for 10 rain at room temperature. Cov- 
erslips were rinsed in TBS and blocked with a mixture of  50% normal rabbit 
serum-5%  BSA  (blocking  solution)  for  30  rain  at  room  temperature. 
Affinity-purified goat anti-guinea pig transghtaminase or IgG fraction of 
preimmune sera were diluted in blocking solution at 10/~g/mi and were ap- 
plied to the coverslips overnight at 4~  The coverslips were washed three 
times for 10 min in TBS containing 0.1% Tween 20. The secondary antibody 
was  TRITC-conjugated  rabbit anti-goat  Ig  (Cappel,  Cochranville,  PA) 
diluted 1:50  in blocking solution. Before use the antibody was dialyzed 
overnight at 40C  against PBS to remove unconjugated fluorochrome and 
preadsorbed with 1/20 vol of FBS for 30 rain at room temperature. Incuba- 
tion with secondary antibody was for 45 at room temperature followed by 
washings as above. Methanol-fixed cells were treated similarly except that 
the  Triton-X  100  permeabilization step  was  omitted.  Coverslips  were 
mounted in 50 % glycerol-TBS containing 0.2 % p-phenylene diamine. Cov- 
erslips were studied on a Nikon Optiphot photomicroscope. Micrographs 
were taken on Kodak Tmax 400 black and white film. 
Quantitation of  Protein-conjugate Polyamines and 
e-(~-glutamyl)-lysine 
Transfected Balb-C 3T3 cells were used for the measurement of the r 
glutamyl)-lysine  (Gln-Lys)  dipoptide  content  24  h  after  they  reached 
confluency. The cells were washed twice with TBS and the acid-precipitated 
fractions were subjected to exhaustive proteolytic digestion (Fesus et al., 
1985).  The protein-free fraction of the digest was passed through an AG- 
50W-X8 column to remove lysine, then the sample was desalted on a silica 
HPLC column using water as eluent. The fraction collected at the position 
of ~(~/-glutamyl)-lysine  was derivatized by phenylisothiocyanate (Bidllng- 
meyer et al., 1984), then analyzed by HPLCflSCO) on a 3.9 mmx  30 cm 
uBondpack CI8 column using the following elution system: eluent A was 
0.14 M sodium acetate with 0.5 ml/liter triethanolamine (pH 6.35), eluent 
B was acetonitrile; isocratic separation at 10% B was carried out for 10 rain 
followed by a linear gradient up to 25%  within 2 rain and a  subsequent 
isocratic separation for 8 rain. The isopoptide  peak was used for the calcula- 
tions and radiolabeled ~(3,-glutamyl)-lysine  was present throughout the pro- 
cedure to follow recovery. 
Protein-conjugate polyamines levels in  transfected Balb-C  31"3 cells 
(24 h  after confluency was reached) were measured by addition of 3H- 
putrescine (5/~Ci) to the culture medium followed  by isolation and quantita- 
tion of conjugated glutamines (Piacentini et al.,  1988).  Determination of 
radiolabeled derivatives was performed on aliquots of enzymatic digests of 
the acid-insoluble fraction, using the automated ion exchange chromatogra- 
phy procedure as described previously (Folk et al.,  1980). 
Protease Detachment Assay 
Adhesivity analyses were carried out by following a modified version of a 
procedure previously described by  DeLuea  et al.  (1990).  Control and 
transglntaminase-transfected  Balb-C 3"1"3 cells were grown in 35-ram  Petri 
dishes, 5/~1 of 3H-labeled amino acids mixture (1 mCi/ml, Sp. Act. 204 
mCi/mg; ICN) were added to each dish 12 hr before the assay. Monolayers 
of cells 24 h after reaching conflucncy were rinsed twice with alpha D-MEM 
medium and 1 ml of 0.125%  bovine trypsin preparation (Gibco BRL) in 
Dulbecco's PBS was added. The dishes were then placed on a rotary shaker 
(American Rotator V; American Dade, Miami, FL) at 80 rpm at room tem- 
perature and 50-i,1 aliquots were taken each 5-10 rain from the dishes. At 
the end of the incubation, the aliquots containing detached cells as well as 
the residual adherent ceils (solubilized in 1% SDS) were quantitated by a 
scintillation spectrometry, 
Results 
Establishment of Transglutaminase-transfected 
Cell Lines 
To express tissue transglutaminase in cultured cells, a 3.3-kB 
eDNA  clone  of  human  endothelial  cell  tissue  trans- 
glutaminase (Clone hTG-1; Gentile et al., 1991) was inserted 
into the ECORI  site of the  eukaryotic expression vector 
pSG5 (Fig. 1). This clone (pSG5-TGase)  included 135 bp of 
5'  untranslated  sequence  of  the  tissue  transglutaminase 
eDNA, 2,061 bp encoding the complete enzyme and 1,058 
bp of 3' untranslated sequence.  To determine whether this 
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Figure 1. Schematic representation of the human tissue transglu- 
taminase expression vector (pSG5-TGase). The vector includes the 
SV-40 early gene enhancer and promoter, intron II of the rabbit 
beta-globin gene, the T7 bacteriophage promoter, a 3.3-kb human 
tissue transglutaminase eDNA cloned into the ECORI site of the 
vector, the SV-40 polyadenylation  signal sequence, and the ampicil- 
lin resistance gene. 
plasmid would support the expression of active transglu- 
taminase in mammalian cells, COS-1 cells were transiently 
transfected with the vector and, after 72  h,  the transglu- 
taminase activity of the cells was determined. Untransfected 
COS-1  cells, or COS-1 cells transfected with pSG5 alone, 
have very low transglutaminase activity (<0.01 pmol/min/ 
mg of cell protein). In the transiently transfected cells the 
transglutaminase  activity was  increased  >45-fold  (0.270 
pmol/min/mg of cell protein). 
Lines of Balb-C 3T3 cells stably expressing tissue trans- 
glutaminase were established by cotransfecting Balb-C 3T3 
cells with pSG5-TGase and a plasmid containing a selectable 
marker  (pSV2-Neo).  Transfected  cells  were  selected  by 
growth in media containing 400 #g/ml G-418 and cell lines 
were  established by cloning cells  from individual G-418 
resistant  colonies.  The  individual  cell  lines  were  then 
screened for the expression of tissue transglutaminase by as- 
says of transglutaminase activity and Western blot analysis 
(Fig.  2).  Untransfected Balb-C 3T3  cells (WT) and cells 
cotransfected with both the pSV2-Neo and the pSG5 (with- 
out insert) vectors show very low transglutarninase activity 
(<0.01  pmol/min/mg  cell  protein)  and  no  tissue  trans- 
glutaminase detectable by Western blot (limit of sensitivity: 
1-2 ng of purified antigen) (Fig. 2, WT and clones 1 and 2). 
Most of the cell lines cotransfected with pSG5-TGase and 
pSV2-Neo  that  were  isolated  as  G418-resistant  colonies 
(clones 4,  6-8,  10,  and  11)  also  showed very low trans- 
glutaminase activity and the absence of immunoreactive tis- 
sue transglutaminase (Fig. 2). Two lines (clones 12 and 9) 
showed low but detectable levels of transglutaminase activ- 
ity.  In  both  of these  lines  immunoreactive tissue  trans- 
glutaminase was also detected by Western blot. In two other 
lines (clones 3 and 5) the enzyme activity was much higher 
(0.2 and 0.78 pmol/min/mg) than the controls and both cells 
gave a strong signal in the Western blot assay.  These lines 
were selected for further characterization. 
To detect the transglutaminase transcripts in the trans- 
fected Balb-C 3T3 cell lines, total RNA from clone 1 (con- 
trol Balb-C 3T3 clone transfected with pSV2-Neo and pSG5) 
and three  clones that expressed  transglutaminase activity 
(clones 3, 5, and 9) was subjected to Northern blot analysis 
with a human tissue transglutaminase eDNA probe (Fig. 3). 
No transcripts were detected in the control clone (lane/); 
clones 3, 5, and 9 contained multiple tissue transglutaminase 
transcripts 0aries 2-4).  Two transcripts (4.2  and 6.2  kB) 
were detected in the clone 3 cells; clone 5 cells contained 
an abundant 2.8-kB transcript as well as minor transcripts of 
4.2 and 5.0 kB. Clone 9 cells contained a single 3.3-kB tran- 
script. It is likely that these transcripts result from random 
multiple integrations of plasmid DNA into the recipient cell 
genome. Initiation of these transfected genes can lead to di- 
verse transcripts accumulating in the transfected cells Oiang 
and Jordan,  1992;  Eghbali et al.,  1990). 
Induction of the Transfected Transglutaminase with 
Sodium Butyrate 
Sodium butyrate has been reported to increase the expres- 
sion of transfected DNA in both transiently and stably trans- 
fected cells (Rouault et al.,  1987).  Fig. 4 (A and B) shows 
the effect of 2 mM sodium butyrate on the expression of tis- 
sue transglutaminase in Balb-C 3T3 control cells (clone 1) 
and two of  the transglutaminase-transfected  cell lines (clones 
3 and 5). Cell extracts were fractionated by SDS-PAGE and 
then either subject to Coomassie blue staining (Fig. 4 A) or 
Western  blot  analysis with  an  antibody  to  tissue  trans- 
glutaminase (Fig.  4  B).  In both  untreated and butyrate- 
treated control cells, the level of tissue TGase is too low to 
be detected by protein staining (Fig. 4 A, lanes I  and 2) or 
short exposure (6 h) of the Western blot autoradiogram (Fig. 
4 B, lanes I and 2). Prolonged exposure (72 h) of the autora- 
diogram (Fig. 4 B, lanes/* and 2*) demonstrated the pres- 
ence of a low level (~10 ng/mg cell protein) of the endoge- 
nous mouse tissue transglutaminase in both untreated and 
butyrate-treated cells. As we have previously reported (Gen- 
tile et al.,  1991) mouse transglutaminase has an electro- 
phoretic mobility slightly faster than the transfected human 
enzyme (compare lanes 1" and 2* with lanes 3-6). 
Sodium butyrate caused a large increase in the level of tis- 
sue transglutaminase in the transfected cell lines.  In un- 
treated clone 3 cells the level of transglutaminase is too low 
to be detected by protein staining, however,  after exposure 
of sodium butyrate, a distinct transglutaminase band (iden- 
tified by the arrow adjacent to lane 4 in Fig. 4 A) can be rec- 
ognized. The level of the enzyme is even higher in the clone 
5  cells.  In these cells the transglutaminase is  sufficiently 
abundant to be detected in untreated cell extracts (identified 
by the arrow adjacent to lane 5). In the butyrate-treated cells 
the tissue transglutaminase is clearly visualized as a promi- 
nent 80-kD polypeptide band (lane 6). 
The level of tissue transglutaminase in the transfected cells 
was quantitated by Western blot autoradiograms (Fig. 4 B). 
In clone 3 cells, the basal concentration of the enzyme is 0.5 
Gentile et al. Expression of Human Tissue T Gases in Balb-C 3T3 Cells  465 Figure 2. Transglutaminase expression in control and expression vector-transfected Balb-C 3T3 cell lines. Transglutaminase activity (A) 
was determined on total cellular homogenates  (10-100 pg of  protein) as described in Materials and Methods. 100/~g  of  total cellular homog- 
enate protein were used for tissue transglutaminase  Western  blot analysis (B) as described in Materials and Methods. WT identifies  untrans- 
fected Balb-C 3"1"3 cells. Clones 1 and 2 are control cell lines transfected with pSG5 vector without a transglutaminase insert and clones 
3-12 are cell lines stably transfected with the pSGS-TGase expression vector. Values of enzymatic activity represent the mean of duplicate 
determinations. 
#g/mg of cell protein (lane 3), in the clone 5 cells it is 1.5 
/~g/mg of cell protein (lane 5). After sodium butyrate treat- 
ment the level of the enzyme increases to 16 txg/mg of cell 
protein in clone 3 (lane 4) and 35/zg/mg of cell protein in 
clone 5 cells (3.5%  of total cell protein) (lane 6). 
Characterization of Transglutaminase in Transfected 
313 Cells 
Previous  studies  reported  that  tissue  transglutaminase is 
mostly recovered in the soluble fraction of cell homogenates 
(Slife et al.,  1986; Juprelle-Soret et al.,  1988) with a small 
fraction of the enzyme present in the particulate compo- 
nents. To determine the subcellular distribution of the en- 
zyme in the transglutaminase-transfected cells, clone 5 cells 
were homogenized and separated into cytosolic and particu- 
late fractions by ultracentrifugation. Tissue transglutamin- 
ase specific activity determined in the total cellular homoge- 
nate was 3,57 pmol/min/mg of protein. The majority of this 
Figure 3.  Tissue transgluta- 
minase transcripts in control 
and expression vector-trans- 
feeted Balb-C 3T3 cell lines. 
Total RNA from control (lane 
1) and the transglutaminase- 
transfected cell lines clone 3 
(lane  2),  clone  5  (lane 3), 
clone 9 (lane 4) was fraetion- 
ated and probed with a 3.3- 
kb radiolabeled human tissue 
transglutaminasr  eDNA  hy- 
bridization  probe. Numbers 
on the fight side identif  T the 
mobility  of RNA  molecular 
mass standards (in kb). 
enzymatic activity (>95 %) was located in the cytosolic frac- 
tion (8.43 pmol/min/mg of protein). The specific activity of 
the enzyme in this compartment was 40-fold higher than in 
the particulate fraction (0.208  pmol/min/mg of protein). 
Isopeptide Conjugates in Transfected  313 Cells 
Tissue transglutaminase catalyzes cross-linking of proteins 
by the formation of e-(,y-glutamyl)-lysyl isopeptide bonds 
(Folk, 1983). To determine the level of the transglutaminase 
activity in intact Balb-C  3T3  cells, the level of the e-('y- 
glutamyl)-lysyl dipeptide was measured by HPLC in enzy- 
matic digests of extracts from control cells and one of the 
transglutaminase-transfected cell lines (clone 5) (Table  I). 
The  average  level  of isopeptide  in  the  transglutaminase- 
transfected Balb-C 3T3 cells was slightly higher (70%) than 
in the control cells.  Sodium butyrate caused a  20-fold in- 
crease in the level of isopeptide in the control cells and an 
even greater increase in the amount of  isopeptide in the clone 
5 cells. 
Transglutaminase  not  only  catalyzes  the  formation of 
isopeptide cross-links, but also the formation of bis-(~,-glu- 
taminyl)-polyamine conjugates. The levels of these conju- 
gates were too low to be detected in nontransfected cells, 
whether or not they were treated with sodium butyrate. They 
were  detectable  (16.5 pmol/mg  protein)  in  the  butyrate- 
treated transfected cells. 
Growth Rate of Transfected 3"13 Cells 
Previous studies have reported that increased transglutamin- 
ase activity often was correlated to reductions in cellular 
proliferation rate (Birckbichler et al.,  1977).  To determine 
whether expression of tissue transglutaminase produced a 
generalized effect on cellular proliferation, we measured the 
proliferative activity of control and transglutaminase-trans- 
fected 3T3  cell clones by 3H-thymidine incorporation dur- 
ing log phase  growth  (Fig.  5).  There  was  no  significant 
difference between the growth rate of the control (clone 1) 
and transglutaminase-transfected cells. To confirm the find- 
ings we also measured the growth rate of control and trans- 
fected cell lines. The doubling time of the transfected cells 
The Journal of Cell Biology,  Volume 119, 1992  466 Figure  4. Effect of sodium butyrate on tissue transglutaminase expression in control and transglutaminase-transfected Balb-C 3T3 cell lines. 
Control (clone 1, lanes 1 and 2) or transglutaminase-transfected (clone 3, lanes 3 and 4; clone 5, lanes 5 and 6) cell lines were cultured 
in media alone (lanes 1, 3, and 5) or media plus sodium butyrate (2 raM, 48 h, lanes 2, 4, and 6). Extracts of the cells were fractionated 
by SDS-PAGE and then either subjected to Coomassie blue staining for proteins (A) or Western blot analysis (B). B (lanes 1-6) were 
obtained after 6 h autoradiography. Lanes 1" and 2* were obtained when the same samples shown in lanes  1 and 2 were subjected to 
autoradiography for 72 h. A (lane 7) contains purified human tissue transglutaminase as a standard.  The arrows adjacent to lanes 4-7 
identify the human tissue transglutaminase band. Tissue transglutaminase amounts were calculated by interpolation with purified human 
tissue transglutaminase standard analyzed by laser densitometry. Purified human red blood cells tissue transglutaminase was a generous 
gift of Dr.  P. J. Birckbickler (Noble Foundation,  Ardmore, OK). 
(clones 3 and 5) of 38 h was not significantly different from 
the doubling time of the pSV2-neo-transfected  control cells 
(tt/2  =  39  h). 
Morphology of Tissue Transglutaminase-transfected 
Balb-C 3T3 Cells 
We  observed that increased  expression  of tissue transglut- 
aminase in Balb-C 3T3 cells increased their adhesive proper- 
ties.  To examine this issue directly we used phase-contrast 
microscopy of formaldehyde-fixed control (clone 1) and trans- 
glutaminase-transfected  (clone 3  and 5) cells (Fig.  6).  The 
control  cells  were  indistinguishable  from  untransfected 
Balb-C  3T3  cells.  The  majority  of cells  showed  a  typical 
Table L Quantitation of  e-(7-glutamyl)-lysyl 
Dipeptide and Spermidine-conjugate Levels in 
Transglutaminase-transfected Clone 5 Batb-C 3T3 Cells 
Clone 1 
(control)  Clone 5 
-NAB  0.26  0.44  ~-(-r-glutamyl)- 
-lysyl dipeptide 
(nmol/mg of protein)* 
N1,N8  Bis-(~(-glytarnyl)  - 
-spermidine 
(nmol/mg of protein)* 
+NAB*  5.10  10.30 
-NAB  ND  ND 
+NAB*  ND  0.165 
* NaB treatment, 2  mM for 48 h. 
$ Each value represents the mean of two different determinations. 
ND, not detectable (<0.05 nmol/mg of protein). 
fibroblastic  morphology,  bipolar  compact  cells  with  well- 
developed lamellipodia (Fig. 6 A). A  few flattened cells and 
occasional phase-bright mitotic cells were also present. The 
transglutaminase-transfected cell lines showed a quite differ- 
ent  morphologic  profile.  The clone  3  cells  showed  an  ex- 
tremely spread and flattened morphology (C).  There were 
very few compact or bipolar cells detectable  even in lower 
power fields. The clone 5 cells showed a more complex mor- 
phologic pattern (Fig. 6 E). This line included many spread 
and flattened cells similar to those seen in clone 3 but it also 
included  numerous  more  compact,  phase-bright,  rounded 













Clone 1  Clone 3  Clone 5 
Figure 5. Growth rate of control and transglutaminase-transfected 
Balb-C 3T3  cell lines.  Control  (Clone  1)  and transglut~-ninase- 
transfected Balb-C 3'1'3 cells (Clones 3 and 5) in log-phase growth 
were pulse  labeled with  3H-thymidine and  the  incorporation  of 
thymidine into DNA was measured by TCA precipitation and scin- 
tillation spectrometry. Values presented represent the mean +  SD 
from three separate experiments. 
Gentile et al. Expression of Human Tissue  T Gases in Balb-C 3T3 Cells  467 Figure 6. Phase-contrast of  control and transglutaminase-transfected cells: effect  of  sodium butyrate. Control (clone 1; A and B) or transglu- 
taminase-transfected (clone 3, C and D; clone 5, E-G) Balb-C 3T3 cells were grown in media alone (A, C, E, and F) or media plus sodium 
butyrate (5 mM, 48 h; B, D, and G). Cells were formaldehyde fixed and photographed under phase-contrast illumination as described 
in Materials and Methods. F shows a higher magnification of clone 5 cells grown in media alone. Bar:  10 #m (A-E, G); 5 #m (F). 
cells.  Unlike  the rounded cells in  the control population 
these cells were not mitotic but were comprised ofinterphase 
cells that showed an extensive membrane blebbing.  These 
cells,  which are better visualized in a  higher power field 
(Fig. 6 F), were actively shedding membrane-limited hema- 
toxylin-negative fragments, a process that leads to the ac- 
cumulation of numerous small  shrunken ceils with intact 
nuclei and an irregular blebbing outline. 
Our previous studies suggested that treatment with sodium 
butyrate increased the level of protein cross-linking in both 
control and  transglutaminase-transfected cells.  This effect 
was paralleled by a marked alteration in the cell morphology 
of the cells (Fig. 7, B, D, and G). In the control 3T3 cells 
(clone 1), sodium butyrate treatment resulted in a spread and 
flattened morphology that was very similar to that seen in 
the transglutaminase-transfected cells (compare B and C). 
Butyrate  treatment  of  the  transglutaminase-transfected 
clones resulted in an even more uniform pattern of extremely 
spread  and  flattened cells  (D and  G).  It  is  notable that 
butyrate treatment suppressed the expression of the pseudo- 
apoptotic cell phenotype in the clone 5 transfected cell popu- 
lation (compare E  and G). 
The Journal of Cell Biology,  Volume 119, 1992  468 Figure 7. Tissue transglutaminase expression in control and transglutaminase-transfected Balb-C 3T3 cells. Control (clone 1, A-C), clone 
3 (D-F) and clone 5 (G-I) Balb-C 3T3 cells were subject to paraformaldehyde  fixation, detergent permeabilization,  and indirect immunoflu- 
orescence microscopy with anti-tissue transglutaminase antibodies as described in Materials and Methods. A and B are from control (clone 
1) cells exposed either to preimmune (A) or immune (B) IgG under standard photographic conditions. C shows the results when control 
cells treated with immune IgG were subjected to an extended exposure times (Sx longer than standard). D-F show clone 3 cells exposed 
to preimmune (D) or immune IgG (E and F). The cells in E were cultured under standard conditions, those in F were exposed to sodium 
butyrate (5 mM) for 48 h.  G-I show clone 5 cells exposed to immune IgG after culture in normal media (G and H) or sodium butyrate- 
containing media (I). H shows a clone 5 cell grown in normal media, exposed to immune IgG, and photographed at a higher magnification 
than the cells in G.  Bar: 5 /~m (D-G and 1); 2.5/zm (A-C and H). 
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glutaminase  in  clone  5  Balb-C 
33"3 cells. Clone 5 transglutamin- 
ase-transfected  Balb-C 3"1"3  cells 
were  fixed  with  methanol  and 
subject  to indirect  immunofluo- 
rescence microscopy with an an- 
titransglutaminase  antibody  as 
described in Materials and Meth- 
ods.  Photographs  are  from  the 
same field subject to either  epi- 
fluorescence  illumination  (A) or 
phase-contrast  microscopy  (B). 
Bar, 5 t~m. 
To evaluate the relationships between transglutaminase ex- 
pression  and  cellular  morphology,  we used  immunocyto- 
chemistry  to visualize  the level of tissue transglutaminase 
expression  in  individual  control  and  transglutaminase- 
transfected 3T3 cells (Fig. 7). A-D show a series of control 
experiments. A and B show the background fluorescence sig- 
nal detected in control (clone 1) cells treated with either pre- 
immune  immunoglobulin  (A) or afffinity-purified  antitrans- 
glutaminase  antibodies (B).  Under photographic  exposure 
conditions adequate to detect transglutaminase e~pression in 
the transfected cells (E-l) there was no background signal 
in control cells. Prolonged exposure (eight times longer) did 
result in minimally  detectable immunospecific  staining  of 
the control cells (C) presumably due to reaction of the anti- 
body with basal level of endogenous tissue transglutaminase 
in Balb-C 3T3 cells. Comparison of transglutaminase-trans- 
fected cells (clones 3 and 5) treated with either preimmune 
(D) or immune antibodies (E, G, and H) demonstrated dif- 
fuse immunospecific staining of the cytoplasm of the trans- 
fected cells.  It was noteworthy that although  all the trans- 
letted  cells  were  immunopositive  there  was  considerable 
variation in the amount of transglutaminase expressed in in- 
dividual cells. These differences were largely obviated when 
the cells were treated with sodium butyrate (F and I), which 
induced an uniform strong immunospecific staining of all the 
transfected  cells.  H shows a  higher  power view of an  in- 
dividual transglutaminase-transfected  cell. The enzyme ap- 
pears to be uniformly distributed throughout the cytoplasm 
of these well-spread cells. The tissue transglutaminase  ex- 
pressed in these cells appears to be largely excluded from the 
nucleus and cytoplasmic vesicles. 
The extensive incubation and washings steps, involved in 
the standard indirect immunofluorescence protocol, resulted 
in the loss of most of the loosely adherent, pseudo-apoptotic 
cells in the clone 5 cell line. When these ceils were retained 
they  showed strong  immunopositive  staining  with  the  an- 
titransglutarninase  antibodies.  The brightly fluorescent cell 
in the lower right  comer of G  is one such cell.  To better 
visualize  the  level  of transglutaminase  in  these  pseudo- 
apoptotic cells, monolayers of clone 5 grown on glass cover- 
slips were subjected to a modified immunofluorescence pro- 
tocol using precipitating fixatives,  minimal incubation times, 
and very gentle washing procedures to retain the majority of 
these cells.  Fig.  8  shows the phase-contrast  and matching 
fluorescence  micrograph  from  such  an  experiment.  The 
phase-contrast  micrograph  (B)  reveals numerous  compact 
cells  with  irregular  outlines  due  to  membrane  blebbing. 
Each of these cells is strongly immunopositive when stained 
with the antitransglutaminase antibodies (A). The strong sig- 
nal in the pseudo-apoptotic ceils compared to the more ad- 
herent,  flattened cells suggested that these cells have very 
high levels of tissue transglutaminase  expression. 
Adhesive Properties of Transfected 3"1"3 Cells 
It  has  been  reported  that  the  induction  of  tissue  trans- 
glutaminase in cells is associated with alteration in cellular 
morphology (Byrd and Licthi,  1987;  Nara et al.,  1989) and 
adhesion (Cai et al.,  1991).  We measured the rate of detach- 
ment of both the Balb-C 3T3 control (clone 1) and two of the 
transglutaminase-transfected  cell lines (clones 3 and 5) after 
exposure to 0.I25%  bovine trypsin preparation  (Fig.  9 A). 
The  transglutaminase-transfected  Balb-C  3T3  were  more 
resistant to protease detachment  than  the control cells.  In 
particular,  clone 5  included  many cells that  required  pro- 
longed exposure to the trypsin preparation before they were 
detached from the culture dish.  Sodium butyrate treatment 
further  increased the resistance  of the transfected cells to 
trypsinization  (Fig.  9 B). 
Discussion 
Transglutaminases  are a family of enzymes that have been 
extensively studied, but an understanding of their physiolog- 
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Figure 9. Trypsin-induced  de- 
tachment of control and trans- 
glutaminase-transfected  Balb-C 
31"3 cell lines. Monolayers of 
control (clone 1) and transglu- 
taminase-transfected  (clones 
3  and  5)  Balb-C 3T3  cells 
were subject to trypsinization 
(0.125 % trypsin, 30 min, 23 ~ 
with shaking) as described in 
Materials and Methods. A rep- 
resents data from cells grown 
in normal media and B from 
cells grown in media contain- 
ing sodium butyrate (2 mM, 
48 h). Values,  expressed as the 
percentage of total cells that 
have detached at the end of  the 
30 min incubation, represent 
the mean •  SD of triplicate 
determinations. 
ical functions has been slow to emerge. It is clear that ex- 
tracellular  transglutaminases,  Factor  xm  and  seminal 
plasma transglutaminase, are involved in the stabilization of 
clots in blood and in seminal plasma, respectively (Green- 
berg et al., 1991). Keratinocyte transglutaminase, an enzyme 
induced during the cornification of squamous epithelia, has 
been shown to contribute to the formation of cross-linked 
protein "envelopes" inside terminally differentiated keratino- 
cytes (Rice and Green,  1978).  However, the physiological 
role of other transglutaminases is less well understood. Tis- 
sue transglutaminase is a relatively ubiquitous intracellular 
transglutaminase that has been studied for many years but lit- 
tle clear evidence exists as to the biological function of this 
enzyme. This enzyme has been implicated in diverse cellular 
functions such  as  growth regulation (Birckbichler et al., 
1978), endocytosis (Davies et al., 1984), secretion (Sener et 
al.,  1985;  Bungay et al., 1986),  cellular morphology (Paye 
et al,, 1986; Byrd and Licthi, 1987; Nara et al., 1989), cellu- 
lar adhesion (Cai et al.,  1991), and most recently in apop- 
totic cell death (Fesus et al.,  1992),  but unambiguous ex- 
perimental evidence for an essential role for the enzyme in 
these processes has been hard to obtain.  The goal of the 
studies reported here has been to develop a novel approach 
to  investigating  the  biological  activity  of  tissue  trans- 
glutaminase. We have selectively increased the level of ex- 
pression of tissue transglutaminase (by expression vector 
transfection) in a cell type that normally expresses very low 
levels of the enzyme and then we have searched for the bio- 
logical  effects attributable  to  the  over-expression  of the 
enzyme. 
One of our major concerns in initiating these studies was 
the feasibility of developing cell lines capable of tolerating 
high levels of intracellular transglutaminase activity. Trans- 
glutaminase induces irreversible protein cross-linking and 
one might anticipate that the expression of high levels of tis- 
sue transglutaminase inside a cell might be associat~ with 
a  profound inhibition of proliferative activity. Several cell 
types,  such as endothelial cells  (Greenberg  et al.,  1987; 
Korner et al.,  1989;  Nara et al.,  1989)  and activated or 
retinoid-stimulated macrophages  (Murtaugh et al.,  1983; 
Moore et al., 1984), have been shown to contain high levels 
of intracellular transglutaminase activity (as much as 1-2 % 
of total cellular proteins), but these cells are usually termi- 
nally differentiated and show little proliferative activity in 
vitro.  Birckbichler  et  al,  (1978) have  shown  that  trans- 
glutaminase activity tends to be very low in undifferentiated 
or rapidly proliferating cell types and to rise when the cells 
are  induced to differentiate or to undergo growth arrest. 
Transglutaminase levels are high in cells undergoing apop- 
totic cell death (Fesus et al.,  1987),  again suggesting that 
expression of the enzyme is associated with terminally dif- 
ferentiated or senescent cells. In spite of these observations, 
the data reported here show that it is possible to isolate via- 
ble cell lines expressing a high level of tissue transglutamin- 
ase. Moreover, in spite of increased levels of  enzyme expres- 
sion (0.2 % of  total cellular protein and 'x,3.5 % after butyrate 
treatment in clone 5) both clone 3 and 5 were stable in long- 
term tissue culture and showed a proliferative activity that 
was comparable to nontransfected or control cells. 
At least two factors may contribute to the viability of cells 
expressing high levels of transglutaminase activity. The first 
of these is that the enzymatic activity expressed in the cells 
appears  to be  largely cryptic in  Balb-C  3T3  cells under 
normal growth conditions. Although the transfected cells 
express high levels of the enzyme, there is only a modest 
increase  in  the  level of cross-linked  proteins  or protein- 
conjugated polyamines in  the  transfected cell  lines.  The 
actual level of isopeptide in both  the  nontransfected and 
transfected cell lines (260-440 pmols/mg) is similar to that 
detected in other cultured ceils and in tissues (Fesus and 
Tarcsa,  1989;  Hand et al.,  1990).  Tissue transglutaminase 
is a Ca2*-dependent enzyme and it is likely that the levels of 
Ca  2+  sufficient to  activate  the  enzyme are  not  normally 
achieved in intact and viable cells (Hand et al., 1985).  Fur- 
thermore, guanine nucleotides have been reported to inhibit 
tissue transglutaminase activity (Achyuthan et al., 1987) and 
some cells have been reported to contain specific intracellu- 
lar transglutaminase inhibitors (Korner et al.,  1989).  The 
low level of cross-linking activity in the intact transfected 
cells suggests that these factors can serve to limit the extent 
of protein cross-linking in ceils expressing even very high 
levels of the enzyme. A less likely possibility, but one that 
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transglutarninase  is unable to utilize the endogenous sub- 
strate proteins present in mouse cells.  Such strict species 
specificity  has not been reported in the literature  of trans- 
glutaminase  biochemistry (Greenberg et al.,  1991). 
A second factor that may favor the viability of cell lines 
transfected  with the transglutaminase  expression vector is 
the variation  in the level of enzyme expressed in individual 
cells.  Immunocytochemical analysis  of both clone 3  and 
clone 5 cell lines  indicated  that  there were marked differ- 
ences in the level of tissue transglutaminase  that accumu- 
lated  in  individual  cells.  Since all  the cells became im- 
munopositive after treatment with sodium butyrate, a drug 
that has been reported to increase the transcriptional  activity 
of transfected DNA (Rouault et al.,  1987),  and since each 
of these lines was cloned from an individual  colony, these 
differences are not likely to be due to genetic heterogeneity. 
We believe they reflect epigenetic variability in the degree to 
which  the  transfected  transglutarninase  construct  is  ex- 
pressed in individual cells. It is possible that individual cells 
with the lowest accumulations  of the enzyme may be capable 
of undergoing mitosis, whereas those cells with very high ac- 
cumulations preferentially  undergo fragmentation and cell 
death.  The heterogeneity of expression of the transfected 
DNA in these clones may have contributed to their viability 
as stable cell lines. 
Transglutaminase and Cellular Adhesion 
Several  recent reports have  linked  the induction  of tissue 
transglutaminase  activity in cells with alterations  in cellular 
morphology (Byrd and Licthi,  1987; Nara et al., 1989) and 
adhesive properties (Cai et al., 1991). Each of these studies 
have used pharmacologic agents (sodium butyrate or retinoic 
acid) to increase endogenous tissue transglutaminase  gene 
expression and it has been uncertain whether the morpho- 
logic changes seen were due to altered transglutaminase  ac- 
tivity or independent effects of the drugs. The observations 
made with the transglutaminase-transfected  cells strongly 
support the idea that increased expression of tissue trans- 
glutaminase can be associated with dramatic alterations  in 
the pattern of interactions  between cells and their substra- 
tum. There have also been reports that transglutarninases  can 
cross-link cytoskeletal proteins in vitro, although the physio- 
logical significance of these observations has not been estab- 
lished (Selkoe et al., 1982). Unlike the control Balb-C 3T3 
cells, the transglutaminase-transfected  cells showed a marked 
flattening  of their  morphology indicating  increased  cell- 
substratum interactions.  This morphologic effect was also 
reflected in an increased resistance of the cells to detachment 
with protease (trypsin).  Therefore,  several independent lines 
of experimental evidence suggest that transglutaminase  ex- 
pression affects cellular adhesiveness. 
The association between transglutaminase  expression and 
increased cellular adhesion poses something  of an enigma. 
The enzyme has classically been considered to be an intra- 
cellular enzyme; the majority of its catalytic activity is found 
in the cytoplasm of cells and yet its biologic effects seemed 
to be linked to alterations  in the interactions between the cell 
and extracellular  proteins.  It is possible that tissue trans- 
glutaminase is involved in the modification of specific intra- 
cellular proteins important for stabilization of cell-substrate 
interactions.  These might be structural  proteins within  the 
cell or the intracellular  domains of receptors involved  in 
adhesion.  However, the studies  carded out with the trans- 
glutaminase-transfected  cells suggested that most of the in- 
traceUular transglutaminase  activity is cryptic and the levels 
of both isopeptide cross-linked  proteins and polyamine con- 
jugates inside cells is very low. An alternative  possibility is 
that the physiological site of tissue transglutaminase  activity 
is actually in the extracellular  compartment. Several proteins 
associated with the extracellular  matrix, such as collagen III 
(Bowness and Tarr, 1990), fibronectin  (Fesus et al., 1986), 
vitronectin  (Sane et al.,  1988),  and nidogen (Aeschlimann 
and Paulsson, 1991) are specific substrates for tissue trans- 
glutaminase activity.  Cell-associated transglutaminase  ac- 
tivity has been shown to promote covalent cross-linking  of 
extracellular  matrix proteins (Tyrrel et al., 1988; Sane et al., 
1991). The enzyme has been shown to bind to both collagen 
(Juprelle-Soret  et al.,  1988)  and  fibronectin  (Turner  and 
Lorand,  1989) and to be readily deposited in the extracellular 
matrix associated with cultured cells and tissues (Upchurch 
et al.,  1987; Thomazy and Fesus,  1989; Aeschlimarm  and 
Paulsson,  1991). We speculate that the high levels of tissue 
transglutaminase  associated with the transglutaminase-trans- 
fected Balb-C 3T3 cells is associated with the cross-linking 
of unidentified  matrix proteins and alterations  in cellular 
adhesiveness.  Further studies on the association between the 
transfected cells and specific matrix proteins will be neces- 
sary to resolve this issue unambiguously. 
Tissue Transglutaminase and Apoptotic Cell Death 
Recently Fesus and his associates have reported on a striking 
association between transglutaminase  activity and the induc- 
tion of apoptotic cell death (Fesus et al., 1987). Tissue trans- 
glutaminase expression is induced and the enzyme accumu- 
lates to high levels in a number of in vitro (Piacentini et al., 
1991) and in vivo (Fesus et al.,  1987; Fesus and Thomazy, 
1988; Davies et al.,  1992) models of apoptosis. Activation 
of the enzyme is apparently  involved in the process of frag- 
mentation  since the membrane-limited  fragments  ("apop- 
totic bodies") shed by apoptotic cells have been shown to 
contain  high  levels  of isopeptide  bonds  and  extensively 
cross-linked proteins (Fesus et al.,  1989).  The results  ob- 
tained with transglutaminase-transfected  cells suggest that 
this association is not incidental.  The Balb-C 3T3 cells that 
expressed highest levels of intracellular  transglutaminase  ac- 
tivity (detected by immunocytochemistry) appear to be un- 
dergoing  active  fragmentation  in  vitro,  their  membranes 
are blebbing and multiple small hematoxylin-negative  mem- 
brane-limited fragments accumulate in the culture media. 
This process is strikingly  similar to some of the processes 
that contribute to apoptotic cell death (Arends and Wyllie, 
1991). 
Apoptotic cells  became dissociated  from neighboring 
cells,  their  cytoplasm becomes condensed, and they  frag- 
ment  into multiple small membrane-limited  fragments (apop- 
totic bodies). These remnants are in turn ingested by neigh- 
boring phagocytic  cells.  A  striking  difference  between the 
morphology of apoptotic cells and that of cells transfected 
with tissue transglutaminase  is that the chromatin of apop- 
totic cells is characteristically condensed and the nucleus it- 
self frequently fragments. We did not detect such changes in 
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fected cells. Thus, expression of high levels of the enzyme 
in Balb-C 3T3 cells seems to reproduce some, but not all, 
of the changes characteristic of cells undergoing apoptotic 
cell death. Our results suggest that the induction and activa- 
tion of tissue transglutaminase in apoptotic cells may con- 
tribute to the active fragmentation of these cells and to the 
subsequent stability of apoptotic bodies. 
Biological Significance of Transgiutaminase 
Expression 
We inaugurated  these studies to gain some insight into the 
biological roles of the enzyme tissue transglutaminase.  At 
least two seemingly distinct processes, alterations in cellular 
adhesion and apoptotic cell death, have emerged from these 
studies as candidates for the physiological functions of this 
enzyme. It is interesting to note that each of these processes 
represents tissue transglutaminase  expressed in a different 
cellular compartment. There is considerable evidence avail- 
able to suggest that the link between transglutaminase activ- 
ity and adhesion involves enzymatic reactions occurring out- 
side the cell. In this environment the Ca  2+ concentration is 
high enough to support transglutaminase activity and the en- 
zyme may be freed from inhibitory factors such as GTP or 
proteins that restrict its activity inside cells. An involvement 
in the processing of extracellular matrix proteins may ex- 
plain the accumulation of tissue transglutaminase  in base- 
ment membrane structures  in tissues, as well as its involve- 
ment in the process of wound healing and tissue repair. An 
unanswered issue is how the enzyme gains access to the ex- 
traceUular  space.  Like  Factor  XIH  and  several  other  ex- 
tracellular proteins tissue transglutaminase does not contain 
a leader peptide or obvious secretory signal and it remains 
to be determined how the enzyme becomes deposited in the 
extracellular compartment. 
While the effects of tissue transglutaminase  on cellular 
adhesion appear to be linked to activation of the enzyme out- 
side the cell, the effects on cellular fragmentation and apop- 
totic cell death may well reflect the consequences of the acti- 
vation of the enzyme inside the cell. Apoptotic cells contain 
levels  of intracellular tissue  transglutaminase  comparable 
to those achieved in the transglutaminase-transfected  fibro- 
blasts. During apoptosis this enzyme appears to be activated 
by increased levels of intracellular Ca  2+. Orrenius and as- 
sociates have shown that Ca  2§ levels rise to levels sufficient 
to activate  intracellular transglutaminase  activity  (Hand et 
al.,  1989;  Orrenius et al.,  1989).  The fact that apoptotic 
cells accumulate both isopeptide cross-linked and protein- 
conjugated  polyamines  indicates  that  the process involves 
activation of the enzyme inside the apoptotic cells.  Thus, 
it seems likely that biological functions of tissue transglu- 
taminase may vary depending on the cellular compartment 
in which the enzyme is both expressed and activated. 
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